Boule Diagnostics – Nomination Committee for the Annual General Meeting 2026
The 2025 Annual General Meeting of Boule Diagnostics AB (publ), (“Boule”), resolved that a Nomination Committee based on the ownership structure on 30 September 2025 shall be appointed to propose the Annual General Meeting 2026:
1. Proposal for Chairman of the Annual General Meeting,
2. Proposal for the Board of Directors,
3. Proposal for Chairman of the Board of Directors,
4. Proposals for fees and other remuneration for Board assignments to each of the Board members and remuneration for committee work,
5. Proposal for auditor,
6. Proposal for fees to the Company’s auditor,
7. Proposal for changes to the principles for the appointment of the Nomination Committee and instructions for the Nomination Committee, to the extent deemed necessary, and
8. Other matters that are the responsibility of the Nomination Committee in accordance with the Swedish Corporate Governance Code
Boule’s largest shareholders at the time above were AB Grenspecialisten, Svolder AB and Thomas Eklund, representing 36 percent of the share capital and votes. These shareholders have in turn nominated Tomas Risbecker (Svolder AB), Katarina Berggren (AB Grenspecialisten) and Thomas Eklund. The Nomination Committee has subsequently constituted itself and elected Katarina Berggren as its Chairman and co-opted the Chairman of the Board Torben Jörgensen. Shareholders who wish to get in touch with the Nomination Committee are welcome to contact the Chairman of the Nomination Committee Katarina Berggren via e-mail at katarina@grenspecialisten.com. In order for proposals to be able to be evaluated by the Nomination Committee in the required manner, such proposals should have been submitted no later than 1 February 2026.
Latest news
-
Kallelse till extra bolagsstämma i Boule Diagnostics AB (publ) 4 Nov, 2026
-
Boule Diagnostics AB resolves on a fully secured rights issue of approximately MSEK 93 with an over-allotment option of up to approximately MSEK 63 subject to approval by the Extraordinary General Meeting 4 Nov, 2026
-
Boule Diagnostics AB beslutar om en fullt säkerställd företrädesemission om cirka 93 MSEK med en övertilldelningsoption om upp till cirka 63 MSEK villkorat av godkännande från extra bolagsstämma 4 Nov, 2026
-
Boule Diagnostics renodlar verksamheten mot förbrukningsvaror, service och OEM – avvecklar instrumentverksamheten 4 Nov, 2026
-
Boule Diagnostics refocuses its operations on consumables, service and OEM – discontinues its instrument business 4 Nov, 2026
-
Boule Diagnostics delårsrapport Q3 2026 23 Oct, 2026
-
Boule Diagnostics Interim Report Q3 2026 23 Oct, 2026
-
Boule Diagnostics Strengthens Long-Term Strategic Collaboration in India 6 Oct, 2026